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Chronic lymphocytic leukaemia (CLL) is themost common adult leu- variability in the choice of starting material (i.e. exosomes, sera or plas-
kaemia in the Western world and is characterized by the accumulation
of CD5+/CD19+/CD23+ mature B cells in the peripheral blood, bone
marrow and lymphoid tissue of patients. Despite major improvements
in therapy over the past decades, CLL remains essentially an incurable
disease. The clinical course of CLL is highly variable with life expectan-
cies running from months to decades. The presence of recurrent chro-
mosomal aberrations along with the mutation status of IGHV genes in
the tumour cells of CLL patients are the current gold standards of clinical
prognostication. However, these tests are laborious to implement and
require techniques not readily available in all diagnostic laboratories.
In this issue of EBioMedicine, Ferrajoli and colleagues propose that plas-
ma and tumour cell-derivedmicroRNAs (miRNAs) encoded by Esptein–
Barr virus (EBV), the causative agent of infectious mononucleosis (also
known as kissing disease), could be useful diagnostic and prognostic bio-
markers for this disease (Ferrajoli et al., 2015). Plasma biomarkers are
an appealing prospect for clinical practice as the ability to directly mea-
sure molecules in the blood of CLL patients (or other types of cancer)
without needing to purify tumour cells would almost certainly lead
lower costs and shorten turnaround times for patients.
The presence of nucleic acids (DNA) in the blood was ﬁrst demon-
strated over 60 years ago (Mandel andMetais, 1948), although their po-
tential as a non-invasive biomarker of cancer was not recognised until
some years later. It was however the 2008 discovery of microRNAs
(miRNAs) in the blood of cancer patients (Lawrie et al., 2008; Mitchell
et al., 2008) that has put the ﬁeld in the spotlight and there are now
more than 4500 publications on the subject (http://www.ncbi.nlm.
nih.gov/pubmed). MiRNAs are particularly attractive candidates as
non-invasive biomarkers as they are able to sub-classify cancers to a
greater degree of accuracy than traditional gene expression analysis
(Lu et al., 2005), and are protected from the high levels of RNase activity
present in blood (Mitchell et al., 2008). Furthermore, unlike protein bio-
markers which can persist in the blood for many weeks, the short half-
life of circulating RNA makes it eminently suitable as a tool to monitor
the evolution of a cancer in real-time allowing treatment decisions to
be taken much more efﬁciently. Despite its promise, the study of circu-
lating miRNA is very much in its infancy reﬂected in the many non-
overlapping and even contradictory studies have been published. On
many occasions this disparity is due to technical factors particularlyDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.04.018.
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methodologies. Perhaps the most serious barrier to translation of
these ﬁndings into the clinic is the low number of patients typically
used for these studies. To their credit the study by Ferrajoli et al. not
only studied a high number of CLL patient samples (n= 516) with sep-
arate test and validation cohorts, but also used three different platform
technologies to detect miRNAs. Moreover, they measured expression
variability of candidate reference genes in the samples. This often
overlooked consideration is crucial for the reliability ofmiRNAdetection
in blood as expression levels of the most commonly used reference
miRNAs can vary signiﬁcantly amongst samples depending upon the
pathology studied (Friedman et al., 2012). In the present study they
found that levels of the EBV-miRNA BHRF1-1 were signiﬁcantly higher
in plasma samples from CLL patients than healthy individuals, and
that patients with higher levels also had high B2M and higher Rai
stage, both indicators of more advanced disease.
Perhaps the most surprising ﬁnding of this publication is that EBV
miRNAs were detectable in individuals without an apparent history of
EBV infection at all (i.e. EBNA-1 IgG seronegative). Plasma samples
from ﬁfteen CLL patients were identiﬁed as being seronegative (also
negative for active EBV infection), yet all of them contained detectable
levels of BHRF1-1 and BART4 miRNAs. The authors suggest that this
anomaly is a reﬂection of the lack of sensitivity of conventional detec-
tion methods. If this really is the case then further research is needed
to address why some infected individuals do not seroconvert. This
could have important implications for the development of vaccines
against EBV infection that has been linked to a range of different malig-
nancies that account for ~200,000 new cancers every year.
Although EBV infection is intimately associated with many different
forms of haematological malignancy, the link with CLL remains contro-
versial not least of all because EBV infection is only rarely detected in
CLL tumour cells, and cells are generally considered refractory to infec-
tion in vitro (Teramoto et al., 2000). However the publication by
Ferrajoli et al. appears to dispute these results as it provides convincing
evidence for the presence of EBVmiRNAs in tumour cells of CLL patients
detected by small RNA sequencing, qRT-PCR and in situ hybridisation.
The authors suggest that the tumour cells are infected but at a level
that it is not detected by conventional methodology. However, anthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(consistent with lack of LMP-1 or EBER expression seen in this study),
but rather that they acquire EBV miRNAs via exosomal transfer. It has
been demonstrated that functionally competent EBV-miRNAs can be
exported from infected B-cells as exosomes and taken up by dendritic
cells (Pegtel et al., 2010). Conversely, malignant B-cells have been
shown to import (non-viral) miRNAs packaged within exosomes
(Mittelbrunn et al., 2011). Therefore it seems plausible that non-
infected CLL tumour cellsmight obtain EBV-miRNAs in a similar fashion,
perhaps from infected non-malignant B-cells or epithelial cell donors
(Temple et al., 2014). Irrespective of the source, these miRNAs are pro-
posed to play a pathogenic role in CLL, as the authors of the present
study demonstrate that over-expression of BHRF1-1 in tumour cells
can inhibit TP53 expression, and that this is consistentwith the observa-
tion that CLL patients with high BHRF1-1 expression have shorter OS.
Although the study by Ferrajoli et al. proposes novel biomarkers for
CLL, the clinical utility of these ﬁndings is questionable as 30–50% of pa-
tients never require therapy at all, and therefore, outside of a clinical
trial context, this information is unlikely to result in changes to patient
management. Nevertheless its publication represents an important
breakthrough in the rapidly emerging ﬁeld of circulating miRnomics.
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